A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Trial to Assess the Efficacy, Safety and Tolerability of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Myocardium, Using an Endomyocardial Delivery System
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- Acronyms CAuSMIc II
- Sponsors Mytogen
- 01 Mar 2017 New trial record